Generation Bio Co (NASDAQ: GBIO)’s stock price has soared by 8.52 in relation to previous closing price of 0.88. Nevertheless, the company has seen a loss of -8.17% in its stock price over the last five trading days. globenewswire.com reported 2025-01-06 that CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq:GBIO) a biotechnology company working to change what is possible for people living with T cell-driven autoimmune diseases, announced it is leveraging its validated T cell-directed lipid nanoparticle (ctLNP) to develop siRNA therapeutics to silence disease-driving targets in T cells. “We are excited to move Generation Bio toward the clinic by deploying our ctLNP to deliver siRNA to T cells. By precisely modulating T cell activity in vivo we believe we can address high-value, currently undruggable targets involved in the inflammation and tissue damage associated with T cell-driven autoimmune diseases,” said Geoff McDonough, M.D., chief executive officer of Generation Bio. “Our aim is to silence therapeutic T cell targets without impacting other immune cell types, unlocking a powerful new application for siRNA in the field. We plan to submit our first IND in the second half of 2026 and to enter the clinic within our cash runway, which is into the second half of 2027.”
Is It Worth Investing in Generation Bio Co (NASDAQ: GBIO) Right Now?
The 36-month beta value for GBIO is also noteworthy at 2.74. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for GBIO is 42.51M, and at present, short sellers hold a 4.15% of that float. The average trading volume of GBIO on January 15, 2025 was 324.02K shares.
GBIO’s Market Performance
GBIO’s stock has seen a -8.17% decrease for the week, with a -19.75% drop in the past month and a -61.02% fall in the past quarter. The volatility ratio for the week is 15.62%, and the volatility levels for the past 30 days are at 13.72% for Generation Bio Co The simple moving average for the last 20 days is -9.22% for GBIO’s stock, with a simple moving average of -61.58% for the last 200 days.
Analysts’ Opinion of GBIO
Canaccord Genuity, on the other hand, stated in their research note that they expect to see GBIO reach a price target of $9. The rating they have provided for GBIO stocks is “Buy” according to the report published on November 08th, 2022.
GBIO Trading at -31.27% from the 50-Day Moving Average
After a stumble in the market that brought GBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.46% of loss for the given period.
Volatility was left at 13.72%, however, over the last 30 days, the volatility rate increased by 15.62%, as shares sank -20.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -57.81% lower at present.
During the last 5 trading sessions, GBIO fell by -8.08%, which changed the moving average for the period of 200-days by -77.40% in comparison to the 20-day moving average, which settled at $1.0503. In addition, Generation Bio Co saw -9.91% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GBIO starting from Quinn Anthony G., who purchase 125,791 shares at the price of $0.96 back on Jan 10 ’25. After this action, Quinn Anthony G. now owns 214,286 shares of Generation Bio Co, valued at $120,759 using the latest closing price.
Quinn Anthony G., the Director of Generation Bio Co, purchase 85,000 shares at $0.97 during a trade that took place back on Jan 13 ’25, which means that Quinn Anthony G. is holding 299,286 shares at $82,450 based on the most recent closing price.
Stock Fundamentals for GBIO
Current profitability levels for the company are sitting at:
- -5.3 for the present operating margin
- 0.76 for the gross margin
The net margin for Generation Bio Co stands at -7.83. The total capital return value is set at -0.45. Equity return is now at value -86.50, with -46.16 for asset returns.
Based on Generation Bio Co (GBIO), the company’s capital structure generated 0.47 points at debt to capital in total, while cash flow to debt ratio is standing at -1.04. The debt to equity ratio resting at 0.9. The interest coverage ratio of the stock is -6.13.
Currently, EBITDA for the company is -133.3 million with net debt to EBITDA at -0.78. When we switch over and look at the enterprise to sales, we see a ratio of 7.3. The receivables turnover for the company is 8.4for trailing twelve months and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.34.
Conclusion
In summary, Generation Bio Co (GBIO) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
